Guoliang Chen

Prof. Guoliang Chen


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YZYongsheng Zhang
Yongsheng Zhang
XLXinjie Liang
Xinjie Liang
XBXuefei Bao
Xuefei Bao
WXWei Xiao
Wei Xiao
GCGuoliang Chen
Guoliang Chen

26 July 2019 in World Journal of Stem Cells
Verified
Journal Article
Closed access
FDFang-Yu Du
Fang-Yu Du
QZQi-Fan Zhou
Qi-Fan Zhou
WSWen-Jiao Sun
Wen-Jiao Sun
GCGuoliang Chen
Guoliang Chen
In recent decades, cancer stem cells (CSCs) have been increasingly identified in many malignancies. CSC-related signaling pathways and their functions provide new strategies for treating cancer. The aberrant activation of related signaling pathways (e.g., Wnt, Notch, and Hedgehog pathways) has been linked to multiple types of malignant tumors, which makes these pathways attractive targets for cancer therapy. CSCs display many characteristic features, such as self-renewal, differentiation, high tumorigenicity, and drug resistance. Therefore, there is an urgent need to develop new therapeutic strategies to target these pathways to control stem cell replication, survival, and differentiation. Notable crosstalk occurs among different signaling pathways and potentially leads to compensatory escape. Therefore, multitarget inhibitors will be one of the main methods to overcome the drug resistance of CSCs. Many small molecule inhibitors of components of signaling pathways in CSCs have entered clinical trials, and some inhibitors, such as vismodegib, sonidegib, and glasdegib, have been approved. Tumor cells are susceptible to sonidegib and vismodegib resistance due to mutations in the Smo protein. The signal transducers and activators of transcription 3 (STAT3) inhibitor BBI608 is being evaluated in a phase III trial for a variety of cancers. Structural derivatives of BBI608 are the main focus of STAT3 inhibitor development, which is another strategy for CSC therapy. In addition to the potential pharmacological inhibitors targeting CSC-related signaling pathways, other methods of targeting CSCs are available, such as nano-drug delivery systems, mitochondrion targeting, autophagy, hyperthermia, immunotherapy, and CSC microenvironment targeting. In addition, we summarize the latest advances in the clinical development of agents targeting CSC-related signaling pathways and other methods of targeting CSCs.

1 July 2019 in Acta Biomaterialia
Verified
Journal Article
Closed access
QQQiujun Qiu
Qiujun Qiu
CLCong Li
Cong Li
YSYanzhi Song
Yanzhi Song
TSTao Shi
Tao Shi
XLXiang Luo
Xiang Luo
YDYihui Deng
Yihui Deng

5 May 2017 in Synthesis
Verified
Journal Article
Closed access
PDF file
GCGuoliang Chen
Guoliang Chen
XBXuefei Bao
Xuefei Bao
ZLZiao Liu
Ziao Liu
XLXinjie Liang
Xinjie Liang
DSDake Song
Dake Song
CBChangshun Bao
Changshun Bao
A synthetic route to 3-formylbenzenesulfonyl chloride derivatives from the corresponding benzaldehydes has been developed. The key step in this procedure is the conversion of aldehyde bisulfite adducts to target compounds via a two-stage reaction in the presence of Na2SO4. A series of 3-formylbenzenesulfonyl chloride derivatives were prepared by this method and identified by chemical derivatization method.

4 August 2019 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
YHYue Hou
Yue Hou
YZYuchen Zhang
Yuchen Zhang
YMYan Mi
Yan Mi
JWJian Wang
Jian Wang
HZHaotian Zhang
Haotian Zhang
CWChun-fu Wu
Chun-fu Wu

1 January 2019 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
CYChunling Yuan
Chunling Yuan
XGXiaoli Guo
Xiaoli Guo
QZQifan Zhou
Qifan Zhou
FDFangyu Du
Fangyu Du
WJWei Jiang
Wei Jiang
LZLibo Zou
Libo Zou